Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2349)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4744)
  2. Department of Medicine (4742)
  3. Center for Pancreatic Cancer Research (2312)
  4. Surgery (1065)
  5. Survivorship Research (1013)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (219)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (147)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (320)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4744)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite-stable colorectal cancer and no active liver metastases
    Meeting Abstract

    Schlechter, B. L.; Fakih, M.; Tsimberidou, A. M.; Bullock, A.; Pimentel, A.; Sharma, S.; Lenz, H. J.; Gordon, M.; Abou-Alfa, G. K.; Marron, T.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • BREAKWATER: Post-hoc subgroup efficacy analyses by chemotherapy ± bevacizumab regimens vs encorafenib plus cetuximab + mFOLFOX6
    Meeting Abstract

    Yoshino, T.; Kopetz, S.; Van Cutsem, E.; Wasan, H. S.; Eng, C.; Yaeger, R.; Kim, T. W.; Ciardiello, F.; Maughan, T.; Desai, J.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
    Meeting Abstract

    Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L. S.; Moehler, M.; Herrero, F. R.; Oh, D. Y.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Quemliclustat and chemotherapy in previously untreated patients with metastatic pancreatic ductal adenocarcinoma: PRISM-1, a randomized, placebo-controlled, phase III trial
    Meeting Abstract

    Macarulla Mercade, T.; Bekaii-Saab, T.; Feeney, K.; O'Reily, E. M.; Pant, S.; Park, J. O.; Prager, G.; Seufferlein, T.; Boakye, M.; He, X.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing claudin18.2 (CLDN18.2): CLARITY-PanTumour01 substudy 3
    Meeting Abstract

    Goyal, L.; Janjigian, Y. Y.; Shitara, K.; Oh, D. Y.; Elimova, E.; Castet, F.; Szekeres, P.; Petrone, M.; Thress, K.; Barker, L.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Body mass index and somatic variants in biliary tract cancers
    Meeting Abstract

    Al Mahmasani, L.; Chou, J.; Capanu, M.; Srivastava, A.; Sigel, C.; Alsuwailem, R.; Berger, M.; Khalil, D.; Harding, J. J.; O'Reilly, E. M.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Final analysis of a randomized, double blind, phase II study of sorafenib with or without YIV-906 in patients with advanced HCC
    Meeting Abstract

    Abou-Alfa, G. K.; Yen, Y.; Harding, J. J.; Whang-Peng, J.; Shi, Y. K.; Yuen, M. F.; Li, X.; Gu, S.; Liu, C.; Jeng, L. B.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • A phase II study of olaparib in patients (pts) with advanced biliary tract cancer (aBTC) with aberrant homologous recombinant repair (HRR) mutations
    Meeting Abstract

    Ahn, D.; Ulrich, A.; Park, W.; McCue, S.; Ou, F. S.; Tran, N.; Fonkoua, L. A. K.; Borad, M. J.; Bekaii-Saab, T.; Javle, M.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Prognostic factors associated with survival for patients with HER2+GEA
    Meeting Abstract

    Bridgewater, J. A.; Su, W.; Sabater, J.; Bowditch, S.; Lin, J.; Ko, A. H.; Ku, G.; Saharia, P.; Madan, T.; Smith, M.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in metastatic gastroesophageal carcinoma (mGEC)
    Meeting Abstract

    Klempner, S. J.; Dayyani, F.; Kratz, J.; Kim, S.; Xu, C.; Ahlers, C. M.; Liu, X.; Chung, J. K.; Sabbatini, P.; Dennis, P. A.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save